Stocksigma LogoStocksigma Logo

Gujarat Themis Biosyn Expands into Global CDMO via MicroBioPharm Japan Acquisition

Gujarat Themis Biosyn completed the acquisition of MicroBioPharm Japan for INR 1,351 Cr, financed via INR 727 Cr QIP and INR 624 Cr mezzanine debt

Gujarat Themis Biosyn Expands into Global CDMO via MicroBioPharm Japan Acquisition

Gujarat Themis Biosyn Ltd 路 Investor Presentation 路 16 Nov 2026, 9:56 pm

Gujarat Themis Biosyn Expands into Global CDMO via MicroBioPharm Japan Acquisition Gujarat Themis Biosyn completed the acquisition of MicroBioPharm Japan for INR 1,351 Cr, financed via INR 727 Cr QIP and INR 624 Cr mezzanine debt, alongside INR 632 Cr debt refinancing. Standalone fermentation capacity doubled from 450 KL to 990 KL. In Q2 FY27, consolidated operations reported revenue of INR 49.9 Cr, an operating EBITDA loss of INR 0.9 Cr, and a net loss of INR 13.8 Cr, impacted by INR 15.57 Cr in unrealized forex losses, higher acquisition financing costs, and partial 13-day MBJ consolidation.

Original exchange filing (PDF)

More announcements from Gujarat Themis Biosyn Ltd

All Gujarat Themis Biosyn Ltd announcements